Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jarushka Naidoo

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Current Oncology (Toronto, Ont.)|July 28, 2023
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor ToxicityChristopher Cluxton, Jarushka Naidoo
The Oncologist|July 24, 2020
A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor ToxicitiesJarushka Naidoo, Karthik Suresh
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2023
PACIFIC in the Real WorldCaroline O'Leary, Jarushka Naidoo
Cancer Metastasis Reviews|July 25, 2022
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancerPhilip Bredin, Jarushka Naidoo
Cancer Metastasis Reviews|August 18, 2022
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancerPhilip Bredin, Jarushka Naidoo
Nature Communications|January 20, 2022
Immune-related adverse events and the balancing act of immunotherapyMichael Conroy, Jarushka Naidoo
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Lung Cancer (Auckland, N.Z.)|November 10, 2021
Immunotherapy for Stage III NSCLC: Durvalumab and BeyondOrla Fitzpatrick, Jarushka Naidoo
Journal of Thoracic Disease|January 12, 2019
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancerBairavi Shankar, Jarushka Naidoo
Clinical Lung Cancer|December 3, 2019
Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung CancerKarthik Suresh, Jarushka Naidoo
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Current Oncology (Toronto, Ont.)|July 28, 2023
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor ToxicityChristopher Cluxton, Jarushka Naidoo
The Oncologist|July 24, 2020
A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor ToxicitiesJarushka Naidoo, Karthik Suresh
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2023
PACIFIC in the Real WorldCaroline O'Leary, Jarushka Naidoo
Cancer Metastasis Reviews|July 25, 2022
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancerPhilip Bredin, Jarushka Naidoo
Cancer Metastasis Reviews|August 18, 2022
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancerPhilip Bredin, Jarushka Naidoo
Nature Communications|January 20, 2022
Immune-related adverse events and the balancing act of immunotherapyMichael Conroy, Jarushka Naidoo
Advances in Experimental Medicine and Biology|December 16, 2015
KRAS-Mutant Lung Cancers in the Era of Targeted TherapyJarushka Naidoo, Alexander Drilon
Lung Cancer (Auckland, N.Z.)|November 10, 2021
Immunotherapy for Stage III NSCLC: Durvalumab and BeyondOrla Fitzpatrick, Jarushka Naidoo
Journal of Thoracic Disease|January 12, 2019
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancerBairavi Shankar, Jarushka Naidoo
Clinical Lung Cancer|December 3, 2019
Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung CancerKarthik Suresh, Jarushka Naidoo
Pageof 18